David Martin, MD, MPH

Vice President, Clinical Safety and Risk Management
Moderna, Inc.

Poster(s):

• (102) Evaluation of postmenopausal hemorrhage following Moderna COVID-19 vaccines: results from surveillance data analysis and interim results from a US claims database cohort study
  Monday, August 26, 2024

  8:00 AM – 6:00 PM CEST

• (125) Reproducibility of computable phenotypes for post-acute sequelae of COVID-19 (PASC) in US administrative claims data
  Monday, August 26, 2024

  8:00 AM – 6:00 PM CEST

• (128) Safety of Moderna mRNA-1273.214 and mRNA-1273.222 COVID-19 bivalent vaccines: results from post-marketing surveillance in South Korea
  Monday, August 26, 2024

  8:00 AM – 6:00 PM CEST

• (279) Post-Marketing Safety Surveillance of Vaccines in Japan for Older Adults: A Feasibility Assessment of Real-World Data Capabilities
  Monday, August 26, 2024

  8:00 AM – 6:00 PM CEST

• (337) Defining a Post-vaccine Myocarditis Cohort by Applying CDC Case Definition to Structured EHR and Claims Data as a Proxy for Case Adjudication
  Tuesday, August 27, 2024

  8:00 AM – 6:00 PM CEST

• (341) Early use of Moderna’s mRNA-1273.815 monovalent vaccine: a descriptive analysis of a US Claims database
  Wednesday, August 28, 2024

  8:00 AM – 1:30 PM CEST

• (367) VAC4EU study to identify risk factors and characterize the clinical course of myocarditis/pericarditis following mRNA-1273 vaccination in four European countries: first descriptive analyses
  Tuesday, August 27, 2024

  8:00 AM – 6:00 PM CEST